June 2015 – Special Issue - Umbilical Cord Blood: Advances and Opportunities

Guest Editors:
Nana Shah, MD, University of Texas
Jan Jaap Boelens, University of Utrecht

Learn more about the Guest Editors here

Since the first umbilical cord blood (CB) transplant for hematopoietic reconstitution in 1988, more than 30,000 CB transplants have been performed. CB transplants are now established as a viable hematopoietic stem cell source worldwide. The resulting experience has not only developed our knowledge of CB transplant but has also opened a new area of research in which CB is used as an active therapy for disease.

This Special Issue published in Cytotherapy focuses on the many advances and potential applications for CB. The guest editors take you from evolving but solidified knowledge of hematopoietic stem cell transplant to the developing experience withadjuvant immunotherapy and further describe the still primordial experience with cord blood / tissue derived mesenchymal stromal cells, IPSCs and therapies beyond cancer including regenerative medicine in genetic diseases.

We are delighted to provide you this Special Issue on achievements in the field of CB and even more thrilled to give an exciting glimpse of the future of this naturally occurring and most plentiful human resource.